Humana Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; financial statements are unaudited. Humana operates through its Insurance and CenterWell health services segments, with Medicare products accounting for approximately 86% of premiums and services revenue.
Financial performance
- Revenue: Total revenue rose 10.7% to $29.6 billion. Premium revenue increased 10.6% to $28.3 billion, primarily on higher Medicare premiums and Medicare Advantage membership growth. Services revenue increased 6.3% to $1.1 billion; investment income rose 49.2% to $288 million.
- Profit: Net income attributable to Humana fell 40.2% to $741 million; diluted EPS declined 38.1% to $6.11. Operating income decreased 28.1% to $1.24 billion. The effective tax rate increased to 25.3% from 22.5%.
- Margins and claims: The consolidated benefit ratio rose to 88.9% from 85.5%, as higher Medicare Advantage medical cost trends and business mix outweighed pricing and benefit-design actions. Favorable prior-period claims development was $535 million, versus $522 million a year earlier, reducing the benefit ratio by about 190 basis points. The operating cost ratio improved to 10.4% from 11.2%, reflecting scale and administrative efficiencies.
- Segments: Insurance operating income declined 32.3% to $898 million; its benefit ratio increased to 89.3% from 86.1%. CenterWell operating income declined 14.5% to $282 million, and its operating cost ratio increased to 93.0% from 91.6%, primarily due to the v28 risk-model revision affecting primary care.
- Cash flow: Operating cash flow was $423 million, compared with $6.7 billion in Q1 2023. The prior-year quarter benefited from a $6.6 billion early Medicare premium remittance because the April payment date fell on a weekend. Investing cash outflow was $414 million and financing cash inflow was $1.21 billion. Cash and cash equivalents ended at $5.91 billion.
- Liquidity and debt: Current assets were $32.8 billion and current liabilities $19.7 billion. Short- and long-term debt totaled approximately $13.2 billion at quarter-end, up from $11.7 billion at year-end 2023; March debt issuance generated $2.2 billion in net proceeds. The company reported $3.98 billion of available capacity under its revolving credit agreements and compliance with its 60% maximum debt-to-capitalization covenant (actual 45.1%). Management believes available cash, investments, operating cash flow and borrowing capacity are adequate for at least the next 12 months.
Material changes and notable items
- Individual Medicare Advantage membership grew 7.7% year over year to 5.55 million; group Medicare Advantage membership grew 7.9%. Stand-alone PDP membership fell 20.6%, state-based contract membership fell 8.0%, and commercial fully insured and ASO medical membership fell 79.0% and 81.3%, respectively, reflecting the planned Employer Group Commercial Medical Products exit.
- Humana repurchased 1.8 million shares for $702 million in the quarter. A new authorization permits up to $3 billion of repurchases through February 15, 2027; approximately $2.96 billion remained available as of April 23, 2024. The quarterly dividend was $0.885 per share.
- Q1 results included a $131 million pretax benefit from put/call valuation adjustments and $29 million of value-creation initiative charges. Management expects additional value-creation charges through the end of 2024. The filing’s reconciliation indicates these specified items increased Q1 diluted EPS by a net $1.01; the comparable specified items reduced prior-year diluted EPS by $0.10.
- Investment securities had $1.4 billion of gross unrealized losses, attributed primarily to higher market interest rates; approximately 97% of debt securities were investment grade. Humana said it did not intend, and was not likely to be required, to sell the securities before recovery, but acknowledged that future fair-value declines or realized losses remain possible.
Outlook, risks and contingencies
- Management describes integrated care and Medicare Advantage growth as strategic priorities. The filing does not provide a clear numeric full-year earnings or revenue guidance figure.
- Humana expects its phased exit from Employer Group Commercial Medical Products to continue. It notes that the exit may affect operating-cost ratios during the transition.
- The CMS Final RADV Rule eliminates the Fee-for-Service Adjuster and provides for extrapolation of audit results beginning with performance year 2018. Humana is challenging the rule in court and says its effects could materially adversely affect results, financial position or cash flows. The company also identifies risk-adjustment data reviews and corrections as potential sources of material impact.
- Other material exposures include government-program and regulatory changes, Medicare Advantage medical cost trends, changes in CMS payments and eligibility, and litigation or investigations. Humana states that losses beyond accrued amounts for the described legal matters cannot currently be reasonably estimated; outcomes could be substantial.
- The current TRICARE East contract is scheduled to expire December 31, 2024; the transition to the successor T-5 contract began in January 2024. All material 2024 CMS Medicare contracts were renewed and 2024 product offerings approved.
- Humana reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. It reported no changes to the risk factors in its 2023 Form 10-K.
Key facts for investors to verify
- Whether Medicare Advantage medical-cost trends and the elevated benefit ratio persist, and how much future earnings benefit from favorable prior-period claims development.
- How the CMS RADV litigation, audit methodology and risk-adjustment reviews may affect Humana’s payments, reserves and cash flows.
- Whether operating cash flow normalizes after the prior-year early CMS remittance and as Medicare receivables and Part D subsidy timing change.
- Progress and costs of the commercial business exit, and whether CenterWell can improve profitability amid the v28 risk-model impact.
- Debt and interest expense trends following the 2024 note issuance, alongside the pace of share repurchases and dividend payments.